IT major Infosys automating integration between own platform, Co-Win

This is to ease the inoculation process for its staff and their families.

infosys
Press Trust of India New Delhi
2 min read Last Updated : Jun 12 2021 | 5:34 PM IST

IT major Infosys on Saturday said it is automating the integration between its own vaccination platform and CoWIN to ease the inoculation process for its staff and their families.

CoWIN head R S Sharma had recently said over a dozen entities, including large digital companies like Paytm, MakeMyTrip and Infosys are looking at approval for offering vaccine bookings.

"As Infosys is in the process of rolling out vaccines for employees and their family, across our Development Centres in India, we are automating integration between our own vaccination platform and CoWIN to make the programme seamless," Infosys said in an emailed statement to PTI.

India has been ramping up vaccination to tackle the COVID-19 pandemic. India has so far administered over 24.9 crore jabs to eligible beneficiaries.

The government had, last month, released new guidelines for the integration of CoWIN with third-party applications, easing the way for such apps to offer vaccine bookings.

Previously, giants like Facebook and Google to startups such as HealthifyMe have introduced a slew of tools to help people find slots for vaccination appointments.

Platforms like Under45 and GetJab became popular overnight as they alerted users when vaccine slots opened up and then directed them to the CoWIN platform to secure an appointment.

The government has been undertaking vaccinations in a phased manner, starting with those over 60 years, then for those over 45 years and most recently, for those aged between 18-44 years.

Initial hiccups like glitches on CoWIN platform and vaccine shortage are also being gradually ironed out.

On Wednesday, the government announced a new update that enables an applicant to correct any inadvertent errors in name, year of birth and gender printed on the CoWIN vaccination certificate.

Users can also make the correction through the CoWIN website.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusInfosys Coronavirus TestsCoronavirus Vaccine

First Published: Jun 12 2021 | 5:34 PM IST

Next Story